PROM1 and neoplasm: On the basis of our preliminary in vivo tumor growth development results, we chose to inject 2×105 CD133+ cells, while 1×107 cells were injected in the CD133-/parental group, so we could compare metabolite variations under similar tumor growth conditions at each stage of our study.